Fk-506 is a –
**Core Concept**
FK-506, also known as Tacrolimus, is a calcineurin inhibitor used in immunosuppressive therapy to prevent organ rejection in transplant patients. It works by inhibiting the activity of calcineurin, a phosphatase enzyme involved in the activation of T-lymphocytes.
**Why the Correct Answer is Right**
FK-506 binds to FKBP-12 (FK506 binding protein 12), a cytosolic receptor, forming a complex that inhibits calcineurin. This inhibition prevents the dephosphorylation of nuclear factor of activated T-cells (NFAT), which is essential for the transcription of interleukin-2 (IL-2) and other cytokines. By reducing IL-2 production, FK-506 suppresses T-cell activation and proliferation, thereby preventing organ rejection.
**Why Each Wrong Option is Incorrect**
**Option A:** FK-506 is not a corticosteroid, which is a different class of immunosuppressive agents that work by reducing inflammation and suppressing the immune response.
**Option B:** FK-506 is not an mTOR inhibitor, which is a class of agents that target the mechanistic target of rapamycin (mTOR) pathway involved in cell growth and proliferation.
**Option C:** FK-506 is not a monoclonal antibody, which is a class of therapeutic agents that recognize and bind to specific antigens on the surface of cells.
**Clinical Pearl / High-Yield Fact**
FK-506 is known for its nephrotoxic effects, which can lead to chronic kidney disease and hypertension in transplant patients. Monitoring of serum creatinine and urine protein levels is essential to prevent long-term kidney damage.
**Correct Answer:** C.